Exciting Developments from Sagimet Biosciences at the Upcoming AASLD 2024
Sagimet Biosciences Inc. (Nasdaq: SGMT), a pioneering biopharmaceutical company dedicated to developing innovative therapies for metabolic and fibrotic disorders, is set to present significant findings at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024. This premier event will occur between November 15 and 19, highlighting cutting-edge research in liver disease and potential novel treatments.
Key Presentations Featuring Denifanstat
The company will showcase Phase 2b data that emphasizes the promising anti-fibrotic effects of its fatty acid synthase (FASN) inhibitor, denifanstat. This research includes compelling preclinical results indicating improvements in atherosclerosis for those receiving treatment with denifanstat. These insights will be shared in three distinct presentations, enriching the conversation around liver disease treatments.
Oral Presentation Spotlight
The first oral presentation focuses on the results from the FASCINATE-2 study. This pivotal study indicates that denifanstat can significantly improve fibrosis and liver health in patients with metabolic dysfunction-associated steatohepatitis (MASH). Following the session scheduled for Sunday, November 17th at 2:45 PM PT, Dr. Mary Rinella from the University of Chicago will detail how AI-based digital pathology tracks improvements in fibrosis and curtails the progression toward cirrhosis in patients facing F2/F3 fibrosis.
Poster Sessions Overview
In addition to the oral presentation, Sagimet will present two poster sessions that delve deeper into denifanstat's potential benefits. The first poster will discuss how the FASN inhibitor reduces atherosclerosis and improves liver health in a mouse model of diet-induced dyslipidaemia with MASH. Scheduled for Friday, November 15, the findings presented by Dr. Wen-Wei Tsai indicate that treatment with denifanstat not only lowers cholesterol levels but also fosters better liver histology, potentially providing cardiovascular and liver health benefits for patients in the future.
Further Insights from Ongoing Research
The final poster presentation promises to offer fresh insights into denifanstat's ability to alleviate liver fibrosis in challenging cases of MASH. Dr. Rohit Loomba from the University of California San Diego will share findings from the Phase 2b trial, which refined standard pathology techniques with AI assessments, illustrating statistically significant fibrosis improvement without exacerbating MASH symptoms.
About Sagimet Biosciences' Vision
Sagimet Biosciences specializes in developing transformative therapies targeting fatty acid synthase (FASN) to address metabolic dysfunction and fibrosis. Their leading therapy, denifanstat, is an oral, once-daily treatment aimed at improving liver health, specifically for MASH patients. The successful completion of the Phase 2b clinical trial underscores Sagimet’s commitment to excellence in addressing liver diseases.
Understanding MASH and Its Challenges
Metabolic dysfunction-associated steatotic liver disease (MASH) is a complex liver disease that affects millions globally. The recent recognition and renaming of this condition from non-alcoholic fatty liver disease to MASH aim to reduce stigma and promote awareness of this serious health issue. Effective treatments remain limited, with only one recently approved drug available in the United States, making the development of therapies like denifanstat critical.
Frequently Asked Questions
What is denifanstat?
Denifanstat is a novel oral FASN inhibitor being developed by Sagimet Biosciences for the treatment of MASH, targeting metabolic and fibrotic dysfunctions.
When and where will Sagimet present its research?
Sagimet will present its findings at AASLD - The Liver Meeting 2024, which takes place from November 15-19 in San Diego.
Why is MASH significant in liver disease research?
MASH is a severe liver disease affecting over 115 million people worldwide, with limited treatment options. Addressing it is crucial for global health.
What role does AI play in their studies?
AI is utilized in digital pathology to assess treatment impacts on fibrosis and steatosis, providing advanced analysis and validation of clinical results.
Where can I find additional information about Sagimet Biosciences?
For more details, you can visit their official website at www.sagimet.com.
